Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Drug-drug interactions when treating HIV-related metabolic disorders.
Expert Opin Drug Metab Toxicol. 2019 Oct;15(10):787-802. doi: 10.1080/17425255.2019.1667334. Epub 2019 Sep 24.
Expert Opin Drug Metab Toxicol. 2019.
PMID: 31512529
Review.
The pharmacological management of cardiovascular disease in people living with HIV (PLWH).
Corbacho N, Mur I, Molas ME, Vidal F, Domingo P.
Corbacho N, et al.
Expert Opin Pharmacother. 2021 Apr;22(6):743-753. doi: 10.1080/14656566.2020.1856075. Epub 2021 Jan 4.
Expert Opin Pharmacother. 2021.
PMID: 33283570
Review.
Item in Clipboard
Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy.
Domingo P, Mateo MG, Villarroya J, Cereijo R, Torres F, Domingo JC, Campderrós L, Gallego-Escuredo JM, Gutierrez MDM, Mur I, Corbacho N, Vidal F, Villarroya F, Giralt M.
Domingo P, et al. Among authors: corbacho n.
J Clin Med. 2022 Jan 22;11(3):549. doi: 10.3390/jcm11030549.
J Clin Med. 2022.
PMID: 35160008
Free PMC article.
Item in Clipboard
Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes.
Domingo P, Quesada-López T, Villarroya J, Cairó M, Gutierrez MDM, Mateo MG, Mur I, Corbacho N, Domingo JC, Villarroya F, Giralt M.
Domingo P, et al. Among authors: corbacho n.
Life Sci. 2022 Nov 1;308:120948. doi: 10.1016/j.lfs.2022.120948. Epub 2022 Sep 9.
Life Sci. 2022.
PMID: 36096241
Free article.
Item in Clipboard
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al.
JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330.
JAMA. 2021.
PMID: 34228774
Free PMC article.
Item in Clipboard
Cite
Cite